Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations (original) (raw)
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
Anne Cross
Neurology and Therapy
View PDFchevron_right
Correction to: Pediatric tumefactive multiple sclerosis case (with baló‑like lesions), diagnostic and treatment challenges
Pelagia Vorgia
Neurological Sciences
View PDFchevron_right
Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)
Adriana Carra
Neurological Sciences
View PDFchevron_right
Correction to: Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy
Supurna Ghosh
Neurochemical research, 2018
View PDFchevron_right
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study
F. Pinardi
Journal of Neurology, 2022
View PDFchevron_right
A network meta-analysis of efficacy and evaluation of safety of subcutaneous Pegylated Interferon Beta-1a and injectable therapies for the treatment of relapsing-remitting multiple sclerosis.
Michael Hutchinson
View PDFchevron_right
Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17-and Activated B-Cells and Correlates with Progression
Mohsen Khademi, J. Christensen
View PDFchevron_right
The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
Anne Cross
Neurology, 2009
View PDFchevron_right
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Gabriel Pardo
Journal of neurology, 2017
View PDFchevron_right
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
Keith Tolley
PloS one, 2015
View PDFchevron_right
RESEARCH ARTICLE A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis
Keith Tolley
2016
View PDFchevron_right
Correction to: Neutrophil-to-Lymphocyte Ratio: a Marker of Neuro-inflammation in Multiple Sclerosis Patients: a Meta-analysis and Systematic Review
Anas elgenidy
SN Comprehensive Clinical Medicine
View PDFchevron_right
Correction: Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA)
Athanassios Kyritsis
PloS one, 2015
View PDFchevron_right
Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?
Bárbara Eizaguirre
Journal of clinical neurology (Seoul, Korea), 2018
View PDFchevron_right
Treatment of multiple sclerosis — success from bench to bedside
Mar Tintoré
Nature Reviews Neurology
View PDFchevron_right
Multiple Sclerosis: Immunopathology and Treatment Update
Maximilian de Courten
Brain sciences, 2017
View PDFchevron_right
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Hans-peter Hartung
Therapeutic Advances in Neurological Disorders, 2021
View PDFchevron_right
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
Eleonora Cocco
Therapeutics and Clinical Risk Management, 2015
View PDFchevron_right
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study
Juhani Ruutiainen, G. Karas, Ronald A van Schijndel, F. Dahlke, Sten Fredrikson
Multiple Sclerosis, 2003
View PDFchevron_right
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis
Giulio Rigon
Reviews, 1996
View PDFchevron_right
Correction: Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55
jorge mena
The Journal of Immunology, 2016
View PDFchevron_right
New treatment strategies in multiple sclerosis
Joanne Jones
Experimental Neurology, 2010
View PDFchevron_right
Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies
Donald Silberberg
Expert Opinion on Investigational Drugs, 2003
View PDFchevron_right
Correction: Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis
Aura Muntasell
The Journal of Immunology, 2011
View PDFchevron_right
Modern multiple sclerosis treatment – what is approved, what is on the horizon
Peter Wipfler, Georg Pilz
Drug Discovery Today, 2008
View PDFchevron_right
A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type
Mohammad Abdollahi
Clinical Therapeutics, 2010
View PDFchevron_right
The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study
peter m. chang
European Journal of Neurology, 2005
View PDFchevron_right
Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice
Mark Freedman, Ludwig Kappos
Multiple Sclerosis and Related Disorders, 2014
View PDFchevron_right
Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis
DIVYANSHU DUBEY
Current Opinion in Neurology, 2016
View PDFchevron_right